India has cut off half the supply of a potential coronavirus treatment touted by Trump


6 April 2020 - Nearly half the supply of hydroxychloroquine to the U.S. comes from makers in India, a flow that has now been abruptly stanched after the Asian nation banned exports of all forms of the malaria drug touted by President Donald Trump as a “game changer” for treating the coronavirus.

According to data compiled by Bloomberg Intelligence, 47% of the U.S. supply of the drug last year came from India makers. 

Only a handful of suppliers in the top 10 are non-Indian, such as Actavis, now a subsidiary of Israeli generics giant Teva Pharmaceutical Industries It’s likely that some of their production facilities are nevertheless located in India, the biggest maker of generic drugs in the world.

Read Time article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Supply , India , COVID-19